Welcome
Advancing Healthcare Through Innovation
Developing an investigational medical technology platform with controlled electrical stimulation and transdermal science.
ABOUT
Our Company
Our Technology
Our Company
Holistic Technologies Inc. was founded in 2018 to develop innovative medical technologies. Through Allevetech, the
company is advancing an investigational platform designed to explore the integration of controlled electrical stimulation with established principles of transdermal transport.
Our Mission
Our Technology
Our Company
Our mission is to advance non-invasive medical technology through thoughtful engineering, rigorous evaluation and
collaboration with clinicians, scientists and research partners.
Our Technology
Our Technology
Our Technology
Meaningful medical innovation requires more than a compelling idea. It requires disciplined engineering, appropriate testing, transparent interpretation of data and respect for the regulatory process. Allevetech is being developed with those principles at the center of the program.
TECHNOLOGY
A Multi-Modal Technology Platform
Exploring the interaction of controlled electrical stimulation and transdermal transport in an integrated medical-device platform.
The Scientific Foundation
Electrical energy has long been studied in medicine and biomedical research. Allevetech's investigational platform is being engineered to generate controlled electrical parameters through purpose-designed applicators while supporting investigation of transdermal transport principles.
Controlled Electrical Stimulation
The platform generates controlled electrical signals using configurable operating parameters. The system is being evaluated through engineering and performance testing to characterize output, consistency and device behavior.
Electroporation
Electroporation is a scientific principle in which electrical pulses have been studied for their ability to transiently alter the permeability of biological barriers. Electroporation has been investigated in a range of biomedical and transdermal-transport contexts. Allevetech is evaluating how principles associated with electroporation may relate to its investigational technology platform. No clinical performance claim is made or implied.
Iontophoresis
Iontophoresis is an established scientific principle involving the use of electrical potential to influence the movement of certain charged or ionic substances. The principle has a history of scientific and medical investigation. Allevetech is evaluating principles associated with iontophoresis as part of its research and development program. No clinical performance claim is made or implied.
Designed as an Integrated System
Rather than presenting individual electrical modalities as stand-alone concepts, Allevetech is developing an integrated platform in which waveform control, applicator design and transdermal-transport principles can be evaluated together.
RESEARCH & DEVELOPMENT
From Concept to Evidence
A structured development program designed to characterize the technology before commercial medical claims are made.
Engineering & Performance
Development includes characterization of electrical output, device performance, applicator behavior, usability and other engineering parameters relevant to the system’s intended regulatory pathway.
Scientific Evaluation
Allevetech evaluates the scientific principles underlying the platform and works with qualified experts to determine appropriate methods for laboratory, technical and clinical investigation.
Clinical Research
Where clinical investigation is undertaken, the objective is to generate evidence under appropriate protocols and regulatory and ethical oversight. Results are interpreted within the scope and limitations of the study design; investigational findings are not presented as established commercial claims.
Regulatory Development
Allevetech is pursuing a U.S. medical-device regulatory pathway. The company’s objective is to support the applicable FDA submission with appropriate technical documentation, performance data and proposed labeling.
Our Standard
We believe medical technology should earn its claims. Until regulatory review is complete, Allevetech will distinguish clearly between scientific rationale, investigational objectives and claims authorized for commercial use.
PAIN & PUBLIC HEALTH
Why Continued Innovation Matters
Pain is a major public-health challenge, and the need for evidence-based approaches remains substantial.
Chronic Pain in the United States
According to the U.S. Centers for Disease Control and Prevention’s National Center for Health Statistics, 24.3% of U.S. adults reported chronic pain in 2023, while 8.5% reported high-impact chronic pain that frequently limited life or work activities.
These figures illustrate the broader public-health impact of chronic pain and the continued need for research and innovation. They are provided for informational context only and do not represent an indication or claim for Allevetech. Allevetech remains an investigational medical-device technology and has not been cleared or approved by the FDA for the treatment of pain or any other medical condition.
The Need for Research
Pain is complex and may have many causes. Appropriate care depends on the individual patient, diagnosis and clinical circumstances. Continued research is needed across multiple disciplines to improve understanding and expand evidence-based options available to clinicians and patients.
Source: CDC/NCHS, National Health Interview Survey, 2023; NCHS Data Brief No. 518 (2024).
OPIOIDS & THE PUBLIC-HEALTH CONTEXT
THE OPIOID CRISIS
The information below provides public-health context for Allevetech’s research and development activities and does not represent an indication or clinical claim for the investigational technology.
A Continuing Need for Innovation in Pain Medicine
A Continuing Public-Health Challenge
Opioid-related overdose deaths remain a major public-health concern in the United States. CDC provisional data estimated 54,743 overdose deaths involving opioids in 2024. That represented a substantial decline from the estimated 83,140 in 2023, but the burden remains significant.
Pain Care and Opioids Require Nuance
Opioids have legitimate medical uses and can be appropriate for certain patients and clinical circumstances. At the same time, opioid misuse, opioid-use disorder and overdose have created profound individual and societal harms. Decisions about opioid prescribing, continuation, tapering or treatment of opioid-use disorder belong with appropriately qualified healthcare professionals and should follow current clinical guidance.
Where Allevetech Fits Today
The opioid crisis is part of the broader public-health context that reinforces the need for continued scientific research and innovation in pain medicine. This broader public-health landscape underscores the importance of continued research and innovation aimed at expanding evidence-based options in pain medicine. The company is developing and investigating a medical-device technology platform incorporating controlled electrical stimulation and transdermal delivery technologies, with the objective of generating the engineering, scientific and clinical evidence needed to support appropriate future medical applications and regulatory review.
The Allevetech medical device is investigational and has not been cleared or approved by the U.S. Food and Drug Administration for commercial distribution in the United States. The information on this page regarding pain and the opioid crisis is provided solely as scientific and public-health context. It should not be interpreted as a claim that Allevetech treats opioid use disorder, reduces opioid consumption, replaces opioid therapy, or has been established as safe or effective for the treatment of pain.
What We Are Committed To
Our role is to develop and evaluate medical technology responsibly. We believe the appropriate path is to generate evidence, complete the applicable regulatory process and communicate only those medical claims that are supported and authorized.
Source: CDC/NCHS provisional 2024 overdose mortality estimates, released May 2025. Data are provisional and may be revised.
SCIENTIFIC COLLABORATION
Advancing the Work Through Collaboration
Connecting with qualified scientific, clinical, engineering and regulatory expertise.
Allevetech values collaboration with professionals and organizations whose expertise can contribute to responsible medical-device development. We welcome appropriate discussions concerning scientific research, engineering, regulatory development and future strategic collaboration.
Areas of Collaboration
• Biomedical and engineering research
• Clinical research planning and execution
• Academic and institutional research
• Device performance and human-factors evaluation
• Regulatory and quality expertise
• Scientific and strategic partnerships
For Qualified Research Professionals
Inquiries regarding participation in appropriately authorized research may be directed to Allevetech. Any investigational use must occur under the applicable regulatory, ethical and study requirements. A website inquiry does not constitute authorization to use or distribute an investigational device.
TEAM
OUR TEAM
Zbigniew (Zib ) Kozak, Co-founder and CEO
Zib has worked in various roles as a consultant ranging from authoring the Environmental Stewardship project in the mining industry to being a leading member in developing risk and security assessments for the FIFA World Cup and the Summer and Winter Olympic Games sponsors. Zib also played a vital role in launching two European brands, Elaspa and Elapromed, in the beauty and wellness sector in Canada.
Barbara Krutchkoff, PhD
Dr. Krutchkoff is an Executive Director of the Institute of Regenerative and Cellular Medicine and Co-Chair of the IRB, which focuses on translational research for regenerative therapeutics. In a span of decades, Barbara has provided strategic assistance for numerous biotech entrepreneurs to help validate novel technologies and therapeutic modalities as well as navigate the regulatory pathway to bring them safely to patients. Currently serving as Chief Scientific Officer, she leads an innovation team at Moda Health, an insurance company looking to reinvent healthcare.
COLLABORATIVE PARTNERSHIPS
We welcome collaboration with healthcare professionals, researchers, academic institutions, public organizations, investors and other qualified partners interested in advancing the responsible scientific, clinical and regulatory development of the Allevetech technology platform and related therapeutic-delivery research.